Ariana Pharma announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies

Ariana® Pharma a leading Artificial Intelligence drug development company announced on April 29th that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies. The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases. Ariana will use its KEM® Explainable Artificial Intelligence technology to identify biomarkers and develop an AI driven therapeutic decision support software. Coordinated by the Institut Imagine, the €10 million funded 5 years collaboration aims at developing disruptive and transformative approaches in the fields of diagnosis, prognosis and therapies to fight pathologies related to the mechanisms of autoimmunity and inflammation in primary immune deficiencies.

For further information, see Ariana Pharma (https://www.arianapharma.com/2021/04/announcement-of-an-artificial-intelligence-driven-precision-medicine/)

Leave a Reply

Your email address will not be published. Required fields are marked *